HanchorBio is a clinical-stage biotechnology company building next-generation cancer and autoimmune therapies on its proprietary Fc-Based Designer Biologics (FBDB) platform. Founded in 2020 by Henlius co-founder Scott Liu, the company engineers multi-target Fc fusion proteins designed to reach tumors that resist conventional PD-1/PD-L1 checkpoint drugs. Its lead candidate, HCB101, is an affinity-optimized SIRPalpha-Fc fusion protein targeting the CD47-SIRPalpha 'don't eat me' pathway, engineered to spare red blood cells and avoid the anemia that sank earlier anti-CD47 programs. With operations spanning Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio is advancing a pipeline across solid and hematologic cancers and autoimmune disease.
Alvin Luk is a biotech executive, neuroscientist and entrepreneur with more than three decades in global drug development. He is President & Chief Medical Officer (Group) and U.S. CEO of HanchorBio, a clinical-stage immunology and immuno-oncology company building Fc-based designer biologics, and co-founder and CEO of CRISPR gene-editing company HuidaGene Therapeutics. Across his career he has contributed to roughly two dozen approved products and more than 250 global regulatory submissions, including LUXTURNA, the first FDA-approved gene therapy. A 2025 TIME100 Health honoree, he wants to turn HanchorBio into the 'Genentech of Asia.'